CLINICAL_TRIALS
trial_result
· 2021-08-17
Clinical Trial Update: A Phase I Trial of Anti-GD2 T-cells (1RG-CART) [Phase 1]
Summary
Phase I trial of anti-GD2 T-cells (1RG-CART) in relapsed or refractory neuroblastoma has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Cancer Research UK | Conditions: Relapsed or Refractory Neuroblastoma | Phase 1 | Status: COMPLETED | Results posted: 2021-08-17